Renaissance Technologies (RenTech)'s BCRX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC (Rentech)) currently holds 2.13 M shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $16.6 M, representing 0.03% of the portfolio. First purchased in 2014-Q1, this long-term strategic position has been held for 38 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained a strategic position in BCRX, demonstrating sustained confidence in this investment. Largest addition occurred in Q2 2025, adding 1.92 M shares. Largest reduction occurred in Q1 2021, reducing 1.21 M shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -11,713 | Reduce 0.55% | 2.13 M | $7.80 |
| Q3 2025 | -386,200 | Reduce 15.28% | 2.14 M | $7.59 |
| Q2 2025 | +1.92 M | Add 317.49% | 2.53 M | $8.96 |
| Q1 2025 | +60,197 | Add 11.04% | 605,218 | $7.50 |
| Q4 2024 | -44,059 | Reduce 7.48% | 545,021 | $7.52 |
| Q3 2024 | -371,100 | Reduce 38.65% | 589,080 | $7.60 |
| Q2 2024 | -630,200 | Reduce 39.63% | 960,180 | $6.18 |
| Q1 2024 | -164,600 | Reduce 9.38% | 1.59 M | $5.08 |
| Q4 2023 | +1.55 M | Add 769.47% | 1.75 M | $5.99 |
| Q3 2023 | +201,845 | New Buy | 201,845 | $7.08 |
| Q4 2022 | -565,380 | Sold Out | 0 | $0.00 |
| Q3 2022 | +438,900 | Add 347.01% | 565,380 | $12.60 |
| Q2 2022 | -125,000 | Reduce 49.71% | 126,480 | $10.58 |
| Q1 2022 | +251,480 | New Buy | 251,480 | $16.26 |
| Q4 2021 | -408,180 | Sold Out | 0 | $0.00 |
| Q3 2021 | -624,300 | Reduce 60.47% | 408,180 | $14.37 |
| Q2 2021 | +965,010 | Add 1430.28% | 1.03 M | $15.81 |
| Q1 2021 | -1.21 M | Reduce 94.73% | 67,470 | $10.17 |
| Q4 2020 | +1.28 M | New Buy | 1.28 M | $7.45 |
| Q1 2020 | -840,734 | Sold Out | 0 | $0.00 |
| Q4 2019 | +629,919 | Add 298.80% | 840,734 | $3.45 |
| Q3 2019 | +210,815 | New Buy | 210,815 | $2.87 |
| Q4 2018 | -217,203 | Sold Out | 0 | $0.00 |
| Q3 2018 | -177,378 | Reduce 44.95% | 217,203 | $7.63 |
| Q2 2018 | -373,222 | Reduce 48.61% | 394,581 | $5.73 |
| Q1 2018 | +371,600 | Add 93.79% | 767,803 | $4.77 |
| Q4 2017 | +169,700 | Add 74.92% | 396,203 | $4.91 |
| Q3 2017 | -178,000 | Reduce 44.00% | 226,503 | $5.24 |
| Q2 2017 | +185,300 | Add 84.53% | 404,503 | $5.56 |
| Q1 2017 | +169,300 | Add 339.26% | 219,203 | $8.40 |
| Q4 2016 | +49,903 | New Buy | 49,903 | $6.33 |
| Q2 2016 | -292,221 | Sold Out | 0 | $0.00 |
| Q1 2016 | +149,318 | Add 104.49% | 292,221 | $2.83 |
| Q4 2015 | +142,903 | New Buy | 142,903 | $10.32 |
| Q2 2015 | -32,403 | Sold Out | 0 | $0.00 |
| Q1 2015 | +32,403 | New Buy | 32,403 | $9.04 |
| Q2 2014 | -90,514 | Sold Out | 0 | $0.00 |
| Q1 2014 | +90,514 | New Buy | 90,514 | $10.58 |
Renaissance Technologies (RenTech)'s BioCryst Pharmaceuticals Investment FAQs
Renaissance Technologies (RenTech) first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q1 2014, acquiring 90,514 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held BioCryst Pharmaceuticals, Inc. (BCRX) for 38 quarters since Q1 2014.
Renaissance Technologies (RenTech)'s largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q2 2025, adding 2,526,734 shares worth $22.64 M.
According to the latest 13F filing for Q4 2025, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC (Rentech), owns 2,128,821 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $16.6 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.03% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 2,526,734 shares, as reported at the end of Q2 2025.